| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/07/2004 | US20040197398 Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor |
| 10/07/2004 | US20040197397 Drug delivery system for treatment of urinary incontinence |
| 10/07/2004 | US20040197396 medicament for the treatment or prophylaxis of a herpes viral infection; high degree of robustness, highly regulated; administering the drug to mammals |
| 10/07/2004 | US20040197394 Stable oral pharmaceutical dosage forms |
| 10/07/2004 | US20040197385 Materials and methods for regulating body weight in non-human animals |
| 10/07/2004 | US20040197383 a print describing calcium-containing dietary product and health effect of consuming a calcium-containing dietary product, the effect includes metabolic consumption of adipose tissue, metabolic change, regulation of body weight, weight loss, reduced weight gain, fat loss, and reduced fat gain |
| 10/07/2004 | US20040197382 Dairy products; calcium carbonate; adjust core temperature of individual; reducing obesity |
| 10/07/2004 | US20040197380 Carbohydrate system and a method for providing nutrition to a diabetic |
| 10/07/2004 | US20040197379 Foods; viscosity lowering polysaccharides; maltodextrin-glucomannan complex; supplying fiber to diabetic individuals |
| 10/07/2004 | US20040197377 Serotonin in liquid phase ; prepackaged drug delivery; antidepressants; obesity therapy; anxiolytic agents; headaches; psychological disorders; sleep disorders |
| 10/07/2004 | US20040197368 Surgical stent and method for preventing occlusion of stented vessels and conduits after implantation of stents |
| 10/07/2004 | US20040197352 Microencapsulaed or enteric coated; therapy for kidney disease; health of gastrointestinal system; probiotic bacteria which reduces creatine or organonitrogen compound |
| 10/07/2004 | US20040197342 Swine plasma albumin; gene expression of immunostimulant; prevent infections; anticancer agents |
| 10/07/2004 | US20040197341 Therapeutic process for p. aeruginosa infections using macrolide antibiotics |
| 10/07/2004 | US20040197340 Pharmaceutical composition based on macrolides for topical application in ophthalmology |
| 10/07/2004 | US20040197339 Deer blood serum containing Borella and antibody thereof |
| 10/07/2004 | US20040197335 Non-myeloablative tolerogenic treatment with tyrphostins |
| 10/07/2004 | US20040197329 Remedies or preventives for rheumatoid arthritis |
| 10/07/2004 | US20040197320 Herbal supplement for increased muscle strength and endurance for athletes |
| 10/07/2004 | US20040197301 Mixture of biocompatible organophosphorus polymer and active materials |
| 10/07/2004 | US20040197294 Cosmetic and/or pharmaceutical preparations |
| 10/07/2004 | US20040197289 Kind of oligosaccharides, their sulfates and dendrimers, and the uses of these compounds |
| 10/07/2004 | US20040197283 Vitamin/metal salt compositions for reducing hair loss and/or promoting hair regrowth |
| 10/07/2004 | US20040197282 Method and preparation containing idebenone for protecting human skin |
| 10/07/2004 | US20040197280 Delivery of medicaments to the nail |
| 10/07/2004 | US20040197273 Suspension aerosol formulations |
| 10/07/2004 | US20040197272 Compositions and methods for therapy for diseases characterized by defective chloride transport |
| 10/07/2004 | US20040197271 Therapy for respiratory system disorders; mixture of adrenergic blocking agent, corticosteroid with propellant; side effect reduction |
| 10/07/2004 | US20040197265 Methods and pharmaceuticals for treating muscle insulin resistance and related conditions |
| 10/07/2004 | US20040194793 Coated nicotine-containing chewing gum, manufacture and use thereof |
| 10/07/2004 | US20040194338 Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| 10/07/2004 | DE4035253B4 Injektionslösungen und Verfahren zu deren Herstellung Injection solutions and processes for their preparation |
| 10/07/2004 | DE10314377A1 Pharmaceutical composition useful for tumor therapy comprises water, oxaliplatin and an acid other than oxalic acid |
| 10/07/2004 | DE10313196A1 Use of an emulsion comprising silicone, emulsifier, salt solution and dimethyl sulfoxide for treating or preventing diseases, e.g. resulting from the accumulation of harmful metabolites |
| 10/07/2004 | DE10313035A1 Methode zur Verstärkung der apoptotischen Wirkung von Zytostatika ohne Erhöhung toxischer Nebenwirkungen Method for enhancing the apoptotic effect of cytotoxic drugs without increasing toxic side effects |
| 10/07/2004 | DE10311921A1 Therapy and/or prophylaxis of cranial-cerebral trauma, cerebral ischemia or Alzheimer's disease, using frankincense-based active agents, e.g. boswellic acid or hydrogenated derivatives |
| 10/07/2004 | DE10311920A1 Therapy and/or prophylaxis of cranial-cerebral trauma, cerebral ischemia or Alzheimer's disease, using frankincense-based active agents, e.g. boswellic acid or hydrogenated derivatives |
| 10/07/2004 | DE10311889A1 Zellpräparat und Verwendung des Präparats zur Behandlung von Gelenken und Knorpeldefekten, sowie Verfahren zur Herstellung Cell preparation and use of the preparation for the treatment of joints and cartilage defects, and methods for preparing |
| 10/07/2004 | DE10311763A1 Verfahren zur Herstellung von 2-Cyan-3-hydroxy-N-(phenyl)but-2-enamiden A process for the preparation of 2-cyano-3-hydroxy-N- (phenyl) but-2-enamides |
| 10/07/2004 | DE10005936B4 Creme zur äußeren Anwendung auf der Nasenhaut Cream for topical application to the skin of the nose |
| 10/07/2004 | CA2561082A1 Anti-inflammatory treatment based on strontium compounds |
| 10/07/2004 | CA2560522A1 Use of compounds for the prevention of drug-induced cell toxicity |
| 10/07/2004 | CA2529311A1 Compounds for the treatment of flaviviridae infections |
| 10/07/2004 | CA2520533A1 Allicin |
| 10/07/2004 | CA2520443A1 Methods for treating inflammatory conditions or inhibiting jnk |
| 10/07/2004 | CA2520440A1 Methods for treating or preventing an inflammatory or metabolic condition by inhibiting jnk |
| 10/07/2004 | CA2520422A1 Compositions for treating angina |
| 10/07/2004 | CA2520403A1 Modulation of cell death |
| 10/07/2004 | CA2520397A1 Activation specific inhibitors of nf-kb and method of treating inflammatory processes in cardio-vascular diseases |
| 10/07/2004 | CA2520307A1 A composition comprising a vanilla extract and use thereof for treating psoriasis |
| 10/07/2004 | CA2520253A1 Interferon-alpha induced gene |
| 10/07/2004 | CA2520057A1 Composition for promoting production of type i collagen and/or elastin |
| 10/07/2004 | CA2520009A1 Oxamide derivatives useful as raf-kinase inhibitors |
| 10/07/2004 | CA2520007A1 Lipid metabolism improving agent |
| 10/07/2004 | CA2519921A1 Asthma preparation |
| 10/07/2004 | CA2519920A1 Use of chemokine receptor agonists for stem cell transplantation |
| 10/07/2004 | CA2519901A1 Bioreductively-activated prodrugs |
| 10/07/2004 | CA2519795A1 Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53 |
| 10/07/2004 | CA2519773A1 Lipid-improving agent and composition containing lipid-improving agent |
| 10/07/2004 | CA2519761A1 Food for improving clinical conditions capable of lowering the concentration of low-molecular-weight nitrogen-containing compounds in blood |
| 10/07/2004 | CA2519707A1 Prostaglandin compositions for the treatment of erectile dysfunction |
| 10/07/2004 | CA2519705A1 Antifungal nail coat and method of use |
| 10/07/2004 | CA2519694A1 Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators |
| 10/07/2004 | CA2519691A1 Angiogenesis promotion by prostaglandin compositions and methods |
| 10/07/2004 | CA2519682A1 Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| 10/07/2004 | CA2519681A1 Use of clusterin for the treatment and/or prevention of peripheral neurological diseases |
| 10/07/2004 | CA2519677A1 Biaryl substituted 6-membered heterocycles as sodium channel blockers |
| 10/07/2004 | CA2519465A1 Elevation of adenosine level by cytokine-induced expression of cd73 |
| 10/07/2004 | CA2519155A1 Formulations comprising an active ingredient and cocoa powder and use thereof |
| 10/07/2004 | CA2519119A1 Formulations comprising tolterodine and cocoa powder and use thereof |
| 10/07/2004 | CA2519053A1 Novel oxazole derivatives, their manufacture and use as pharmaceutical agents |
| 10/07/2004 | CA2519051A1 Water-soluble thalidomide derivatives |
| 10/07/2004 | CA2519038A1 Oral delivery system comprising an antibacterial and an anti-inflammatory agent |
| 10/07/2004 | CA2518854A1 Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor |
| 10/07/2004 | CA2518793A1 Methods of inducing immunotolerance and compositions for use therein |
| 10/07/2004 | CA2518792A1 Methods and means to suppress symptoms of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (gitr or tnfrsf18) |
| 10/07/2004 | CA2517831A1 Use of ritonavir for the treatment of unconjugated hyperbilirubinemia |
| 10/07/2004 | CA2517828A1 Compositions and methods for treatment of premature ejaculation |
| 10/07/2004 | CA2516163A1 High viscosity xanthan polymer preparations |
| 10/07/2004 | CA2515691A1 Comestibles containing isomaltulose and trehalose for sustained carbohydrate energy release and reduced glycemic/insulinemic responses, and for preserving osmolality |
| 10/06/2004 | EP1464706A2 HEK5, HEK7, HEK8, HEK11, EPH-like receptor protein tyrosine kinases |
| 10/06/2004 | EP1464673A2 Polyanhydrides with biologically active degradation products |
| 10/06/2004 | EP1464646A1 Thieno(2,3-C) Isoquinolines for use as inhibitors of Parp |
| 10/06/2004 | EP1464645A1 Indole derivative |
| 10/06/2004 | EP1464641A1 4-Phenyl-piperazinyl, -piperidinyl and tetrahydropyridyl derivatives as dopamine D4 antagonists |
| 10/06/2004 | EP1464640A2 20-Epi-16-ene-25-OH-D3-analogs |
| 10/06/2004 | EP1464636A1 Novel substance having antitumor/anti-inflammatory activity |
| 10/06/2004 | EP1464339A1 Cell migration inhibitor |
| 10/06/2004 | EP1464337A1 Regulation of intracellular glucocorticoid concentrations |
| 10/06/2004 | EP1464336A1 Use of tryprostatin A for the reversal of cancer drug resistance |
| 10/06/2004 | EP1464335A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist |
| 10/06/2004 | EP1464334A1 Decontamination agent against prions |
| 10/06/2004 | EP1464333A2 Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders |
| 10/06/2004 | EP1464332A1 Combination of nicergoline and riluzole for the prevention and treatment of motoneuronal disorders |
| 10/06/2004 | EP1464331A1 Compressed oral pharmaceutical dosage form, with an enteric coating, which contains an acid-labile benzimidazole compound |
| 10/06/2004 | EP1464330A1 Use of a composition containing oligosaccharides in combination with a saponine or a basic aminoacid, for topical administration or for inhalation |
| 10/06/2004 | EP1463832A2 Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 86604 |
| 10/06/2004 | EP1463827A2 LIMKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 10/06/2004 | EP1463823A2 Methods of increasing endogenous erythropoietin (epo) |
| 10/06/2004 | EP1463820A1 Method of screening compounds |